TY - JOUR
T1 - A pilot study evaluating dosing tolerability of 17α-estradiol in male common marmosets (Callithrix jacchus)
AU - Sathiaseelan, Roshini
AU - Isola, Jose V.V.
AU - Santín-Márquez, Roberto
AU - Adekunbi, Daniel
AU - Fornalik, Michal
AU - Salmon, Adam B.
AU - Stout, Michael B.
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to American Aging Association 2024.
PY - 2024
Y1 - 2024
N2 - 17α-estradiol extends healthspan and lifespan in male mice without significant feminization or deleterious effects on reproductive function, making it a candidate for human translation. However, studies in animal models that more accurately replicate human physiology are necessary to establish 17α-estradiol dosing standards for clinical trials. This study evaluated the tolerability of 17α-estradiol treatment in the common marmoset over a short treatment duration. We found that male marmosets tolerated two dosing regimens (0.37-0.47 or 0.62-0.72 mg/kg/day) as evidenced by the absence of gastrointestinal distress, changes in vital signs, or overall health conditions. 17α-estradiol treatment mildly decreased body mass, adiposity, and glycosylated hemoglobin, although these changes were not statistically significant in most instances. However, neither dose of 17α-estradiol elicited feminization in our study, thereby suggesting that optimized dosing regimens may provide health benefits without feminization in primates. Additional studies are needed to determine if longer duration treatments would also be nonfeminizing and elicit significant health benefits, which would aid in developing dosing regimens targeting healthy aging in humans.
AB - 17α-estradiol extends healthspan and lifespan in male mice without significant feminization or deleterious effects on reproductive function, making it a candidate for human translation. However, studies in animal models that more accurately replicate human physiology are necessary to establish 17α-estradiol dosing standards for clinical trials. This study evaluated the tolerability of 17α-estradiol treatment in the common marmoset over a short treatment duration. We found that male marmosets tolerated two dosing regimens (0.37-0.47 or 0.62-0.72 mg/kg/day) as evidenced by the absence of gastrointestinal distress, changes in vital signs, or overall health conditions. 17α-estradiol treatment mildly decreased body mass, adiposity, and glycosylated hemoglobin, although these changes were not statistically significant in most instances. However, neither dose of 17α-estradiol elicited feminization in our study, thereby suggesting that optimized dosing regimens may provide health benefits without feminization in primates. Additional studies are needed to determine if longer duration treatments would also be nonfeminizing and elicit significant health benefits, which would aid in developing dosing regimens targeting healthy aging in humans.
KW - Androgen
KW - Endocrinology
KW - Estrogen
KW - Follicle stimulating hormone
KW - Luteinizing hormone
KW - Nonhuman primate
UR - http://www.scopus.com/inward/record.url?scp=85200689594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85200689594&partnerID=8YFLogxK
U2 - 10.1007/s11357-024-01311-z
DO - 10.1007/s11357-024-01311-z
M3 - Article
C2 - 39107620
AN - SCOPUS:85200689594
SN - 2509-2715
JO - GeroScience
JF - GeroScience
ER -